The economic burden of noncervical human papillomavirus disease in the United States.
about
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United StatesThe role of HPV in head and neck cancer and review of the HPV vaccineCosts and effectiveness of neonatal male circumcisionCost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United StatesCost analysis of Human Papillomavirus-related cervical diseases and genital warts in SwazilandEconomic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre.HPV Infection-Associated Cancers: Next-Generation Technology for Diagnosis and TreatmentMeta-analysis of human papillomavirus infection concordance.Economic burden of human papillomavirus-related diseases in Italy.Burden of human papillomavirus infection and related comorbidities in men: implications for research, disease prevention and health promotion among Hispanic men.Cost-effectiveness of surveillance strategies after treatment for high-grade anal dysplasia in high-risk patientsClinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasiaHealth and economic implications of HPV vaccination in the United States.Human papillomavirus vaccination for boysThe Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future OpportunitiesComparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.Applying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran.Human papillomavirus vaccination: current indications and future directionsCharacteristics and survival of head and neck cancer by HPV status: a cancer registry-based study.The HPV E6 oncoprotein targets histone methyltransferases for modulating specific gene transcription.Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.The Influence of Religiosity and Spirituality on Rural Parents' Health Decision Making and Human Papillomavirus Vaccine ChoicesIncidence and cost of anal, penile, vaginal and vulvar cancer in DenmarkThe Human Papillomavirus Vaccine: Current Perspective and Future Role in Prevention and Treatment of Anal Intraepithelial Neoplasia and Anal Cancer.Primary prevention and vaccination for penile cancer.Annual cost of hospitalization, inpatient rehabilitation, and sick leave for head and neck cancers in Germany.Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b triFinancial implications of male circumcision scale-up for the prevention of HIV and other sexually transmitted infections in a sub-Saharan African communityChimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.Impaired T Cell-dependent Humoral Immune Response Associated with Juvenile-onset Recurrent Respiratory Papillomatosis ProgressionDevelopment of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesionsDescription of a pilot anal pap smear screening program among individuals attending a Veteran's Affairs HIV clinic.Cost-Effectiveness Evaluation of Quadrivalent Human Papilloma Virus Vaccine for HPV-Related Disease in IranTargeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.Oncogenic impact of human papilloma virus in head and neck cancer.Cost–effectiveness of catch-up programs in human papillomavirus vaccination.The cost effectiveness of human papillomavirus vaccines: a systematic review.A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.Medical Care Cost of Oropharyngeal Cancer among Texas Patients.Developments in L2-based human papillomavirus (HPV) vaccines.
P2860
Q22306233-2BC845A5-A136-4439-837B-0C601234C4A6Q24630128-2D9C8E87-62AE-4530-817D-8EE67D1CA4F5Q24630822-EB78BC31-743C-4DC9-AE25-4BA146CEA815Q24655328-6BD919F1-AC7F-4FE4-BCD4-75E67F2521EEQ33713018-3AC3FBF9-4C4C-496B-8CA2-7D2CEF8BBE9CQ33852632-36DA9002-804C-4587-BB04-0080CB79F919Q34290170-DBC88515-147F-4257-96A5-F98A7E9E6214Q34293114-48FC444B-1C9D-48F1-B730-2125DE8DB9B0Q34490403-0C25BCB8-50FB-4339-AF7C-7C4E152CD198Q34572271-8C94BAE1-4903-495E-A2BF-F6BABA294540Q34619704-F8D89340-5A45-4776-9451-80BB6406D46CQ34625933-7DF846F3-915B-443C-903F-186732DD08CDQ34824304-5F0894B0-BBA1-450E-B204-E9B5EB419698Q34994792-E3553722-C16E-48C7-B4B2-7826546D761FQ35185640-92272B45-D759-4DAA-90D2-8B985C5752A9Q35235306-DFCB0467-7027-4CA8-8DD8-5E54D257E20BQ35484171-49737799-E541-4C58-A9F1-BF3859C70903Q35558593-4E35EB32-9E51-4ACE-8C2E-250D2C9B9098Q35870672-76E535B8-8B6A-4CC0-B216-91F9536D68BBQ35949401-0BDE18A7-477D-4B52-93B8-7DB0C027F2ADQ35991580-FDCFA7AB-DDD3-497F-B7D4-14E2F6F9C283Q36238916-DE84376F-A402-4493-8C1C-D0FDA791E74CQ36536178-C347DC11-FC8F-47C0-AF8C-722B65A7C506Q36788317-F32B7612-E4F6-48C5-896E-762FBDA6E885Q36847922-69556B3E-0561-4159-BAE2-DB07DE5F61B6Q36870624-09D26225-F62B-4833-934B-9C8EE92B8870Q36954152-2FABC55A-72F7-46B4-A116-9A08F3CC31F0Q37117397-6C9809F1-0C0F-4C5F-9C3F-CE622D256A32Q37356046-A0059223-7A0D-43F3-8BE7-8629C8834AD1Q37399606-91D18679-FB68-47C9-BE86-E26FCAEF0D50Q37511930-38B7CD8F-8C26-469D-AA22-6479552A1203Q37550347-9839D5A1-0CB7-47EC-A065-C0FEBCE9C8E8Q37687207-6A214A49-BAF1-4EBD-A766-163193C7C28EQ37696770-D3D8C2C5-B3EB-48B7-9784-9CF0283CE480Q37762309-90176F92-9040-473B-9FCC-03F14E03A54DQ37798010-EB3E129D-1DBE-4471-AC2C-F997C2AFD67EQ37993109-8B4F5952-7091-44BE-9F49-509360BD0F5CQ38006991-65D39F6D-EB1B-4F4B-8C71-CA3B6471F60BQ38609505-1ED58F53-D2CC-46C6-80EC-DF0A47CC87DAQ39021001-60F11CC6-7AD6-40DE-9D3F-18FC3704A568
P2860
The economic burden of noncervical human papillomavirus disease in the United States.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The economic burden of noncervical human papillomavirus disease in the United States.
@ast
The economic burden of noncervical human papillomavirus disease in the United States.
@en
type
label
The economic burden of noncervical human papillomavirus disease in the United States.
@ast
The economic burden of noncervical human papillomavirus disease in the United States.
@en
prefLabel
The economic burden of noncervical human papillomavirus disease in the United States.
@ast
The economic burden of noncervical human papillomavirus disease in the United States.
@en
P2860
P1476
The economic burden of noncervical human papillomavirus disease in the United States.
@en
P2093
Delphine Hu
P2860
P304
P356
10.1016/J.AJOG.2008.03.064
P407
P50
P577
2008-05-01T00:00:00Z